Xiaodong Wang Sells 41,760 Shares of Beigene, Ltd. (NASDAQ:ONC) Stock

Beigene, Ltd. (NASDAQ:ONC) insider Xiaodong Wang sold 41,760 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $261.28, for a total transaction of $10,911,052.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Xiaodong Wang also recently made the following trade(s):

• On Tuesday, March 4th, Xiaodong Wang sold 8,146 shares of Beigene stock. The stock was sold at an average price of $254.58, for a total transaction of $2,073,808.68.

Beigene Stock Down 4.0 %

Shares of ONC stock opened at $251.98 on Friday. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. Beigene, Ltd. has a 12 month low of $126.97 and a 12 month high of $287.88. The stock has a market cap of $24.79 billion, a price-to-earnings ratio of -30.58, a PEG ratio of 7.73 and a beta of 0.65.

Beigene (NASDAQ:ONC) last issued its earnings results on Thursday, February 27th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.55). Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The firm had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.09 billion. As a group, equities analysts predict that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on ONC. Macquarie raised their price target on shares of Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. Bank of America raised shares of Beigene from a “neutral” rating to a “buy” rating and raised their price target for the stock from $207.00 to $320.00 in a research note on Monday, March 3rd. Guggenheim reissued a “buy” rating on shares of Beigene in a research note on Friday, February 28th. Sanford C. Bernstein set a $259.00 target price on shares of Beigene in a research note on Thursday, March 13th. Finally, JMP Securities set a $348.00 target price on shares of Beigene in a research note on Friday, February 28th.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.